Moreover, injecting recombinant ACE2 markedly increase serum ACE2 but not urinary ACE2 (19), uACE2 reflects ACE2 release from proximal tubules (20, 21) and increases in both humans and mice with CKD and diabetic kidney disease (DKD) (21, 22). Here, ACE2 is linked to chronic kidney disease.